Suits Against Health Care Employers
Liability claims against health care facilities, including hospitals and nursing homes, often include claims of negligent hiring, supervision and/or credentialing in addition to the "traditional" theories of medical malpractice litigation. For many years, state courts debated whether a hospital's alleged acts in credentialing physicians fell within the scope of the "treatment and care" of patients. While the majority of jurisdictions now appear to recognize private causes of action against a health care facility based upon alleged improper hiring, retention or credentialing of professional staff, there is no uniformly accepted standard of care nationwide. Accordingly, specialists and the occasional practitioner in this litigation field are equally well advised to monitor the developing common law of their jurisdiction in the litigation of cases presenting such claims.
Intricacies of the Class Action Fairness Act
Most medical malpractice attorneys deal primarily with individual clients and local medical providers and institutions. Sometimes, however, a case has broader reach, crossing state lines and encompassing claims by several plaintiffs. If the case is a class action lawsuit, a whole different set of rules and procedures come into play.
Features
Drug & Device News
Recent news of importance to you and your practice.
OIG Report Cites Feds
State medical licensing boards and hospitals rely on many information sources when making licensing and credentialing decisions. One major source of information is the National Practitioner Data Bank (NPDB), a reporting system managed by the Health Resources and Services Administration (HRSA). Last month, the reliability of the information contained in the NPDB was called into question after reporting failures within the federal government itself were exposed by a report issued by the Office of the Inspector General (OIG). The OIG found that three Health and Human Services (HHS) agencies had failed to report as many as 474 medical malpractice cases that should have been reported to the NPDB over the course of several years.
Merck Wins Big in Jersey Vioxx Trial
The nation's second trial over health effects of the drug Vioxx got swamped in New Jersey last month, as a jury categorically rejected claims that failure to warn about the painkiller's risks caused a user's heart attack. The jury found, 8-1, that Merck & Co. properly alerted prescribing physicians to a link between Vioxx and an increased risk of cardiovascular events, and found unanimously that there were no consumer-fraud violations in the way Merck marketed Vioxx to physicians. As a result, the jury never reached the question of proximate causation of postal worker Frederick "Mike" Humeston's heart attack.
Features
Confronting Medical Error
In September of this year, a medical malpractice suit pending in Wilkes-Barre, PA, generated significant publicity as the case proceeded to trial. In that case, plaintiffs Tukishia and William Bobbett filed suit against Mercy Hospital and several physicians following the death of their 4-year-old son in the hospital's emergency room. The child, Torajee Bobbett, died after spending more than 9 hours at the hospital on July 19, 2001 into July 20, 2001, without obtaining proper treatment, according to documents filed in the court record. Several aspects of plaintiffs' claim related to alleged deficiencies with the Emergency Department's policies, procedures and staffing at the time Torajee was treated.
Features
Why CA's Anti-SLAPP Statute Should Apply to Peer Review
California law protects defendants from lawsuits designed to thwart "a person's right of petition or free speech under the United States or California Constitution in connection with a public issue." The "anti-SLAPP" (Strategic Lawsuit Against Public Participation) statute provides this protection by permitting the defendant to move to strike the plaintiff's complaint at the outset of litigation unless the plaintiff can demonstrate a likelihood of success on the merits of the claim. (Cal. Code Civ. Proc., ' 425.16, subd. (e)).
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- Bankruptcy Sales: Finding a Diamond In the RoughThere is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- The DOJ's Latest Opioid Crime-Fighting Tool: The Civil False Claims Act<b><i>The U.S. Department of Justice Is Now Using The False Claims Act — Traditionally a Civil Enforcement Tool — to Combat the United States' Sweeping Opioid Epidemic</b></i><p>The use of the FCA is part of a larger DOJ strategy to develop multi-faceted solutions for this public health emergency.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
